Your search for Odevixibat returned 2 results

The sNDA is supported by data from the ASSERT study, which included patients less than 17 years old with genetically confirmed Alagille syndrome.

Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor.